Literature DB >> 7105383

Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma.

P H Konits, M J Egorin, D A Van Echo, J Aisner, P A Andrews, M E May, N R Bachur, P H Wiernik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7105383     DOI： 10.1007/BF00255484

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  8 in total

1.  Experimental, clinical, and metabolic studies of thiopurines.

Authors:  E B ELION; S W CALLAHAN; G H HITCHINGS; R W RUNDLES; J LASZLO
Journal:  Cancer Chemother Rep       Date:  1962-02

Review 2.  Chemotherapy of colorectal carcinoma.

Authors:  P V Woolley; J S Macdonald; P S Schein
Journal:  Semin Oncol       Date:  1976-12       Impact factor: 4.929

3.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Clin Gastroenterol       Date:  1976-09

4.  Hematuria and crystalluria after high-dose 6-mercaptopurine administration.

Authors:  M J Duttera; R L Carolla; J F Gallelli; D S Gullion; D E Keim; E S Henderson
Journal:  N Engl J Med       Date:  1972-08-10       Impact factor: 91.245

5.  Pharmacology of 6-thioguanine in man.

Authors:  G A LePage; J P Whitecar
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

6.  Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-THIOGUANINE (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel.

Authors:  J Horton; A Mittelman; S G Taylor; L Jurkowitz; J M Bennett; E Ezdinli; J Colsky; J A Hanley
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

7.  Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine.

Authors:  C A Presant; A E Denes; L Klein; S Garrett; G E Metter
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

8.  Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans.

Authors:  P A Andrews; M J Egorin; M E May; N R Bachur
Journal:  J Chromatogr       Date:  1982-01-08
  8 in total
  7 in total

1.  Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study.

Authors:  D H Shevrin; L J Kilton; T E Lad; M Mullane; B Esparaz; R Knop; J Egner; P Johnson; R Blough; S French
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 2.  The thiopurines: an update.

Authors:  Sally Coulthard; Linda Hogarth
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

3.  6-Thioguanine: high-dose 2-H infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; M B van Leeuwen; J M van Baal; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

4.  Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.

Authors:  J A Ajani; R Pazdur; R J Winn; J L Abbruzzese; B Levin; C Wiseman; M A Lenado-Lee; Y Z Patt; I H Krakoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

5.  Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.

Authors:  J A Ajani; R Pazdur; R J Winn; J L Abbruzzese; B Levin; R Belt; J Young; Y Z Patt; I H Krakoff
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 6.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

7.  Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

Authors:  L Lennard; H A Davies; J S Lilleyman
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.